Addressing the unmet needs in patients with type 2 inflammatory diseases: when quality of life can make a difference.

Autor:	Gómez de la Fuente E; Department of Dermatology, University Hospital Alcorcon Foundation, Madrid, Spain., Alobid I; Rhinology and Skull Base Unit, Department of Otorhinolaryngology, Hospital Clínic, IDIBAPS, CPERES, Barcelona University, Barcelona, Spain., Ojanguren I; Pneumology Service, University Hospital Vall d'Hebron, VHIR, CIBERES, Autonomous University of Barcelona, Barcelona, Spain., Rodríguez-Vázquez V; Allergology Service, University Hospital Complex of Santiago, University of Santiago Compostela, A Coruña, Spain., Pais B; Quality and Patient Safety Unit, Quality Subdirectorate, Healthcare Area of Santiago de Compostela y Barbanza, Servizo Galego de Saúde, Santiago de Compostela, Spain., Reyes V; Regional Ministry of Health of Andalusia (CSJA), Adviser, Sevilla, Spain., Espinosa M; Asociación Española de Esofagitis Eosinofílica (AEDESEO), Madrid, Spain., Luca de Tena Á; Asociación de Afectados por la Dermatitis Atópica (AADA), Madrid, Spain., Muerza I; Asociación de Apoyo a Personas Afectadas por el Asma de Bizkaia (ASMABI), Bilbao, Spain., Vidal-Barraquer E; Alira Health, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in allergy [Front Allergy] 2023 Nov 09; Vol. 4, pp. 1296894. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).
DOI:	10.3389/falgy.2023.1296894
Abstrakt:	Background: Patients with asthma (AS), atopic dermatitis (AD), allergic rhinitis (AR), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic urticaria (CU), non-steroidal anti-inflammatory drugs-exacerbated respiratory disease (N-ERD), and certain phenotypes of chronic obstructive pulmonary disease (COPD), among others, have a common underlying pathogenesis known as Type 2 inflammation (T2i). These diseases often coexist with other T2i conditions and have a substantial impact on the quality of life (QoL) of patients. However, limited data on patients' experiences, perspectives, and current management of T2i diseases have been published thus far. Aims: This survey, promoted by the patient-driven T2i Network Project, aimed at identifying the common drivers and challenges related to the QoL of patients with T2i diseases by putting the patient's perspective at the force and including it in the design of new care strategies. Methodology: An anonymous online survey was carried out through convenience sampling between May and June 2023. The survey was codesigned by members of different patient associations, healthcare professionals and healthcare quality experts, and implemented using EUSurvey and distributed through eight patient associations from Spain. The survey consisted of 29 questions related to the participant's sociodemographic features, a series of self-reported multiple choice or rating scale questions, including diagnosis, QoL measures, disease severity, healthcare resource utilization, and quality of care. Results: The survey included 404 participants, members from eight patient associations, the majority of whom had moderate-to-severe self-reported disease severity (93%) and one or more coexisting pathologies related to T2i (59%). Patients with more than one pathology had a significantly greater impact on QoL than those with only one pathology ( p  < .001). Participants with self-reported severe symptoms reported significantly worse QoL than those with mild-to-moderate severity ( p  < .001). More than half of the patients (56%) felt constantly bothered by the unpredictability of their illness caused by potential exposure to known or unknown disease triggers. The lack of coordination between specialists and primary care was also expressed as an area of dissatisfaction by participants, with 52% indicating a complete lack of coordination and 21% indicating an average coordination. Conclusion: This article reports the initial findings of a patient-led initiative, which highlights the common QoL challenges faced by individuals with type 2 inflammation-related diseases and emphasizes the importance of further clinical research to improve the management of this patient group. Considering the significant impact on QoL, a multidisciplinary approach integrated into new healthcare protocols has the potential to improve patient management and QoL, shorten the time to diagnosis and reduce healthcare resource utilization. Competing Interests: This publication is the result of collaborative research performed between patients, doctors and healthcare quality experts with the coordination and supervision of Alira Health Company. EG declares to have received honoraria for consultancy and conferences from Lilly, Janssen, FAES Farma, Almirall, Abbvie, Novartis, Leo-Pharma, Pfizer and Sanofi. IA declares to have received honoraria for consultancy and conferences from Viatris, Roche, Sanofi, GSK, MSD, Menarini, Astrazeneca, Salvat, Galenus Health, Olympus, and Novartis. IO declares to have received honoraria for consultancy and conferences from Astrazeneca, Boehringuer-Ingelheim, Chiesi, Novartis, Astrazeneca, GSK, Puretech and Sanofi. He has also received financial aid from Astrazeneca, Bial, and Chiesi for congress attendance and has received grants from Sanofi for research projects. VR declares to have received honoraria for consultancy and conferences from GSK, ALK and Sanofi. EVB was employed by Alira Health. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (© 2023 Gómez de la Fuente, Alobid, Ojanguren, Rodríguez-Vázquez, Pais, Reyes, Espinosa, Luca de Tena, Muerza and Vidal-Barraquer.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu